The Simoa HD-X is the very latest fully automated technology platform from Quanterix, conveying unprecedented levels of sensitivity, robustness, and throughput to Pharmacokinetic-Pharmacodynamic (PK-PD) bioanalytical studies.
“We chose to go with the Quanterix Simoa HD-X automated analyzer because its robustness and ultra-sensitivity is up to 1000x greater than traditional immunoassays. It offers reproducibility, convenience of sample-to-answer, is automated and offers multiplexing capabilities well suited to help advance our customers’ large molecule projects!" says Michael Akoh, Managing Director at Wieslab Laboratory Services.
"With the newest addition to our technology expertise, we are able to extend our service offering with single molecule array digital ELISA as a capability. This technique enables Wieslab Laboratory Services to offer reliable biomarker analyses at much lower concentrations than previously possible. We can now measure six biomarkers in a single assay at fg/ml concentrations in biomarker projects.” says Janka Ryding, Director of Bioanalytical Services at Wieslab Laboratory Services.
The first validated marker on this platform is Neurofilament Light (NfL), an important biomarker for general neurodegeneration. The Simoa technology enables reliable measurement of different biomarkers at much lower concentrations than ever before.
Over the coming months Wieslab Laboratory Services will extend the range of validated assay service offerings and this addition to our technology expertise, brings the benefits of ultra-sensitive multiplexing to our laboratory service customers.
Wieslab Diagnostic Services now offer NfL testing from serum, using Simoa, and from CSF. We also offer fast and accurate clinical testing for a wide range of other diagnostic markers.